

Pharmacy & Therapeutics Committee Meeting

Notice of Public Meeting

State of Alaska
Department of Health & Social Services

Division of Health Care Services

The Division will be sponsoring the following meeting to address the Preferred Drug List.

Please note, as a result of COVID-19 this meeting will be available via webinar only.

Please register for the meeting by using the link below:

https://magellanhealth.zoom.us/webinar/register/WN_YUiMDHojTJ6iExdS1kGyRg

If you are calling in only through the webinar:

***6 to Toggle mute/unmute and *9 to Raise Hand**

After registering, you will receive a confirmation email containing information about joining the webinar.

The Pharmacy and Therapeutics Committee will meet Friday, November 19, 2021 at 8:00 a.m. Agendas are posted on the Health Care Services Preferred Drug List Program Overview website <https://manuals.medicaidalaska.com/docs/pharmacy.htm>.

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until November 5, 2021 at 4:00pm AK local time. Forms may be found at: <https://manuals.medicaidalaska.com/docs/pharmacy.htm>

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items, by utilizing the Clinical Submission form found at: <https://manuals.medicaidalaska.com/docs/pharmacy.htm>. A conflict of interest form must accompany any submission. Submissions should be received no later than November 17, 2021 to allow inclusion in the meeting. If you can not join the webinar and would like to join via teleconference, please dial 1.800.315.6338, use access code 24251#.

Individuals with disabilities who need special accommodations in order to participate should contact Charles Semling at 907.334.2458 no later than 2:00 p.m., Wednesday, November 17, 2021.

**Alaska Medicaid Pharmacy and Therapeutics Committee Meeting
November 19, 2021**

Please note, as a result of COVID-19 this meeting will be available via teleconference only

Please register for the meeting by using the link below:

https://magellanhealth.zoom.us/webinar/register/WN_YUiMDHojTJ6iExdS1kGyRg

If you are calling in only through the webinar:

*6 to Toggle mute/unmute and *9 to Raise Hand

After registering, you will receive a confirmation email containing information about joining the webinar.

Agenda

For anyone unable to access the webinar: 1.800.315.6338.

Access code **24251#**

1. **Call to Order – Chair** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment**

The Department’s methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where ***new information exists and industry testimony will be taken*. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

***New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.*

4. Class Review, Discussion & Vote

AK Treatment Class	Drug Class	Status
Cystic Fibrosis	CFTR Potentiator Agents	BLUE**
	Antibiotics, Inhaled	GREEN
	Pancreatic Enzymes	GREEN
Central Nervous System	Multiple Sclerosis Agents	RED**
	Stimulants & Related Agents	RED**
	Sedative Hypnotics	BLUE**
	Anticonvulsants	BLUE**
	Antipsychotics – Atypical	RED**
	Antidepressants	BLUE**
Analgesics	Alzheimer’s Agents	RED**
	NSAIDS	BLUE**
	Analgesics, Opioid – Short Acting	BLUE**
	Analgesics, Opioid – Long-Acting	BLUE**
	Neuropathic Pain	BLUE**
	Antimigraine Agents	BLUE**
	Skeletal Muscle Relaxants	GREEN
Restless Leg Syndrome (RLS)	GREEN	

Substance Dependence	Smoking Cessation Products	BLUE**
	Opioid Dependence	GREEN
	Opioid Reversal Agents	BLUE**
Antiviral Monoclonal Antibodies	Respiratory Syncytial Virus	GREEN

5. **Break as needed** – 15 minutes
6. **Review minutes** from **September 2021** meeting
7. **Comments from Committee Members or Chair**
8. **Adjourn**

Next Meeting Date: January 21, 2022

NOTICE OF PUBLIC MEETING

State of Alaska
Department of Health & Social Services
Division of Health Care Services

The Division will be sponsoring the following meeting to address the Drug Utilization Review.

Please note, as a result of COVID-19 this meeting will be available via teleconference only.

The Drug Utilization Review Committee will meet Friday, November 19, 2021 at 1:00 p.m. Agendas are posted on the Health Care Services Drug Utilization website <https://manuals.medicaidalaska.com/docs/pharmacy.htm>. If you would like to join via teleconference, please dial 1.800.315.6338, use access code 24251#.

Any pharmaceutical manufacturer may submit unsolicited material related to the agenda items by utilizing the Clinical Submission form. Clinical Submissions will be accepted until November 5, 2021 at 4:00pm AK local time. Forms may be found at: <https://manuals.medicaidalaska.com/docs/pharmacy.htm>

Any member of the public, including health care professionals, may submit unsolicited material related to the agenda items by sending an email to charles.semaling@alaska.gov or via mail to 4601 Business Park Blvd, Bldg K, Anchorage, AK 99503. A conflict of interest form must accompany any submission.. Submissions should be received no later than November 17, 2021 to allow inclusion in the meeting.

Individuals with disabilities who need special accommodations in order to participate should contact Charles Semling at 907.334.2458 no later than 2:00 p.m., Wednesday, November 17, 2021.



Alaska Medical Assistance DUR Committee Meeting
Friday, November 19, 2021
Frontier Building, 3601 C Street; Room 896
1:00 p.m.
1.800.315.6338, access code 24251#

Please note, as a result of COVID-19 this meeting will be available via teleconference only.

Agenda

- (1) Review of minutes from September
- (2) Review of Agenda
- (3) Comments/Suggestions from Committee members
- (4) Overview of Medicaid Prescription and Cost Trends
- (5) Prospective Drug Utilization Review / Clinical Topic Areas:
 - a. New Prescription Medications (Interim PA List – 6 month review)
 - i. Review of new medications to market since the April meeting
 - b. New Prior Authorizations, Quantity Limits, Edits
 - i. Lybolvi
 - ii. Kerendia
 - iii. Verquvo
 - iv. Myalept
 - c. Review of existing Prior Authorizations, Quantity Limits, Edits
 - i. Hepatitis C
 - ii. Lidoderm
- (6) Opioid Use Trends and ICD-10 Report
- (7) Covid Claims Review
- (8) FDA/DEA Updates
 - a. FDA Drug Safety Communications
- (9) FAERS Reports
- (10) Misc. DUR items
- (11) End of Public Meeting
- (12) Profile Review

Pharmaceutical Manufacturers wishing to submit unsolicited clinical information may do so via the form found at the link below:

<https://manuals.medicaidalaska.com/docs/pharmacy.htm>

Submissions for the November meeting must be received no later than 4pm Alaska local time on November 5, 2021.